AbbVie (ABBV) FCF Margin (2012 - 2026)
AbbVie (ABBV) reported FCF Margin of 23.76% for Q1 2026, up 1326.0% year-over-year from 1.67% in Q1 2025, and down 19.25% on a QoQ basis from 29.42% in Q4 2025.
AbbVie (ABBV) has 15 years of FCF Margin data on file, last reported at 23.76% in Q1 2026.
- Quarterly FCF Margin rose 1326.0% year-over-year to 23.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 31.81% (up 499.0% YoY) and the FY2025 annual result came in at 29.13%, down 252.0% from the prior year.
- FCF Margin declined to 23.76% in Q1 2026 per ABBV's latest filing, from 29.42% in the prior quarter.
- Across five years, FCF Margin topped out at 52.81% in Q3 2023 and bottomed at 10.49% in Q1 2025.
- The 5-year median for FCF Margin is 33.34% (2022), against an average of 34.79%.
- The widest annual swing landed in 2024, when FCF Margin slumped 3025 bps; it then soared 1763 bps in 2025.
- Tracing ABBV's FCF Margin over 5 years: stood at 47.72% in 2022, then sank by 33 bps to 31.8% in 2023, then surged by 41 bps to 44.74% in 2024, then slumped by 34 bps to 29.42% in 2025, then decreased by 19 bps to 23.76% in 2026.
- Per Business Quant, the three latest ABBV FCF Margin figures stand at 23.76% (Q1 2026), 29.42% (Q4 2025), and 42.11% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.59% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.76% |
| Dec 31, 2025 | 29.42% |
| Sep 30, 2025 | 42.11% |
| Jun 30, 2025 | 31.67% |
| Mar 31, 2025 | 10.49% |
| Dec 31, 2024 | 44.74% |
| Sep 30, 2024 | 35.95% |
| Jun 30, 2024 | 14.04% |
| Mar 31, 2024 | 31.25% |
| Dec 31, 2023 | 31.80% |
| Sep 30, 2023 | 52.81% |
| Jun 30, 2023 | 44.29% |
| Mar 31, 2023 | 32.87% |
| Dec 31, 2022 | 47.72% |
| Sep 30, 2022 | 50.13% |
| Jun 30, 2022 | 33.34% |
| Mar 31, 2022 | 35.06% |
| Dec 31, 2021 | 32.84% |
| Sep 30, 2021 | 53.81% |
| Jun 30, 2021 | 33.63% |
| Mar 31, 2021 | 36.04% |
| Dec 31, 2020 | 33.01% |
| Sep 30, 2020 | 43.50% |
| Jun 30, 2020 | 27.93% |
| Mar 31, 2020 | 42.81% |
| Dec 31, 2019 | 35.75% |
| Sep 30, 2019 | 51.90% |
| Jun 30, 2019 | 28.46% |
| Mar 31, 2019 | 37.17% |
| Dec 31, 2018 | 39.36% |
| Sep 30, 2018 | 51.51% |
| Jun 30, 2018 | 33.24% |
| Mar 31, 2018 | 31.84% |
| Dec 31, 2017 | 31.04% |
| Sep 30, 2017 | -1.60% |
| Jun 30, 2017 | -1.63% |
| Mar 31, 2017 | 30.70% |
| Dec 31, 2016 | 21.00% |
| Sep 30, 2016 | 20.85% |
| Jun 30, 2016 | 27.70% |
| Mar 31, 2016 | 33.69% |
| Dec 31, 2015 | 28.41% |
| Sep 30, 2015 | 34.12% |
| Jun 30, 2015 | 1,604.67% |
| Mar 31, 2015 | 28.57% |
| Dec 31, 2014 | -13.41% |
| Sep 30, 2014 | 32.00% |
| Jun 30, 2014 | 31.97% |
| Mar 31, 2014 | 10.67% |
| Dec 31, 2013 | 21.40% |
| Sep 30, 2013 | 35.74% |
| Jun 30, 2013 | 40.88% |
| Mar 31, 2013 | 25.39% |
| Dec 31, 2012 | 16.25% |
| Sep 30, 2012 | 50.29% |
| Jun 30, 2012 | 32.65% |
| Mar 31, 2012 | 34.32% |